CVS Health Corporation $CVS Holdings Cut by Chiron Capital Management LLC

Key Points

• Chiron Capital Management LLC reduced its stake in CVS Health Corporation by 40.4% in Q1, selling 10,402 shares, and now holds 15,328 shares valued at over $1 million.
• Several institutional investors, including Vanguard Group Inc. and Dodge & Cox, increased their stakes in CVS Health during the same quarter, collectively reflecting significant interest in the company.
• CVS Health's stock has received multiple upgrades from analysts, with price targets reaching as high as $84.00, indicating strong market sentiment towards the company's performance and future outlook.

Chiron Capital Management LLC lowered its position in CVS Health Corporation (NYSE:CVS - Free Report) by 40.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,328 shares of the pharmacy operator's stock after selling 10,402 shares during the quarter. Chiron Capital Management LLC's holdings in CVS Health were worth $1,038,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in CVS. McIlrath & Eck LLC lifted its holdings in CVS Health by 32.6% in the 4th quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock worth $32,000 after buying an additional 174 shares in the last quarter. Saudi Central Bank acquired a new position in CVS Health in the 1st quarter worth $34,000. Costello Asset Management INC lifted its holdings in CVS Health by 281.3% in the 1st quarter. Costello Asset Management INC now owns 572 shares of the pharmacy operator's stock worth $39,000 after buying an additional 422 shares in the last quarter. Stone House Investment Management LLC acquired a new position in CVS Health in the 1st quarter worth $39,000. Finally, Park Square Financial Group LLC bought a new stake in shares of CVS Health in the 4th quarter worth about $43,000. Institutional investors and hedge funds own 80.66% of the company's stock.

CVS Health Stock Performance

Shares of NYSE:CVS traded up $0.07 during trading on Friday, reaching $73.76. 5,074,859 shares of the company's stock traded hands, compared to its average volume of 5,804,935. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.80 and a quick ratio of 0.62. CVS Health Corporation has a 12 month low of $43.56 and a 12 month high of $74.53. The company has a 50 day moving average of $66.60 and a 200-day moving average of $66.00. The stock has a market capitalization of $93.56 billion, a P/E ratio of 20.60, a price-to-earnings-growth ratio of 0.81 and a beta of 0.62.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.46 by $0.35. The business had revenue of $98.92 billion during the quarter, compared to the consensus estimate of $94.87 billion. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The company's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.83 EPS. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts expect that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, August 1st. Shareholders of record on Tuesday, July 22nd were paid a $0.665 dividend. The ex-dividend date was Tuesday, July 22nd. This represents a $2.66 annualized dividend and a dividend yield of 3.6%. CVS Health's dividend payout ratio (DPR) is presently 74.30%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CVS. Cantor Fitzgerald reissued an "overweight" rating and issued a $78.00 target price on shares of CVS Health in a research report on Tuesday, August 26th. Wall Street Zen raised shares of CVS Health from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Baird R W raised shares of CVS Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. UBS Group raised shares of CVS Health from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $67.00 to $79.00 in a research report on Monday, August 18th. Finally, Morgan Stanley boosted their target price on shares of CVS Health from $80.00 to $82.00 and gave the stock an "overweight" rating in a research report on Friday, August 1st. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $77.89.

Insider Activity at CVS Health

In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of the firm's stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total value of $532,650.00. Following the sale, the director owned 22,156 shares in the company, valued at approximately $1,573,519.12. This trade represents a 25.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.22% of the company's stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.